一个病例报告,描述了沃里科纳和simnotrelvir/ritonavir之间的药物相互作用
Tingting Chen1, Qingquan Zhang1
1Department of Pharmacy, Quanzhou First Hospital, Quanzhou, Fujian, China.
Frontiers in antibiotics
|November 21, 2025
概括
同时使用simnotrelvir/ritonavir和沃里康纳可能会增加沃里康纳水平. 这项案例研究突出显示,在并发使用时,伏利康纳的最低度显著增加,需要剂量调整和治疗药物监测.
科学领域:
- 药理学 药理学是指药理学的学科.
- 传染性疾病 传染性疾病
背景情况:
- 由于预期的沃里可纳水平下降,与西蒙特雷尔维尔/里托纳维尔与沃里可纳的同时使用是禁忌的.
- 之前没有关于simnotrelvir/ritonavir和voriconazole之间的药理学相互作用的报道.
研究的目的:
- 报告一例同时服用伏利可纳和simnotrelvir/ritonavir的病例.
- 在临床环境中研究这两种药物之间的药理动力相互作用.
主要方法:
- 一个88岁的男性肺部阿斯伯吉洛症和COVID-19联合感染的案例研究.
- 在与simnotrelvir/ritonavir同时使用之前,期间和之后测量伏利康纳的最低度.
- 治疗药物监测和调整voriconazole的剂量.
主要成果:
- 经过两天的同时使用,伏利康纳的最低度从2.8和2.6mg/L增加到6.0mg/L.
- 伏利康纳剂量减少了25%,即使在停止使用simnotrelvir/ritonavir后,相互作用仍然存在.
- 在simnotrelvir/ritonavir停用四天后,沃里康纳水平仍然很高 (3.5 mg/L),需要持续监测和剂量调整.
结论:
- 同时使用simnotrelvir/ritonavir可显著增加沃里康纳的最低度.
- 西蒙特雷尔维尔/里托纳维尔和沃里科纳之间的药理动力相互作用需要仔细监测治疗药物和动态剂量调整.
- 当这些药物同时使用时,临床警至关重要,尽管产品插入禁忌.
相关概念视频
Pharmacokinetics: Drug–Food and Drug–Viral Interactions
189
A drug interaction occurs when the concurrent use of another drug, food, or an external substance alters the pharmacological activity of a drug. This interaction can modify the action of the original drug, affecting its effectiveness and safety.Drug–food interactions are significant as they impact drug absorption, metabolism, and excretion. For example, grapefruit juice is a well-known disruptor of drug metabolism. It inhibits the cytochrome P450 3A4 enzyme, crucial for the metabolism of...
189
Pharmacokinetics: Drug–Drug Interactions
329
Drug interactions occur when the pharmacological effect of one drug is altered by another substance, either enhancing or diminishing its activity. The drug whose activity is altered is known as the object drug, and the substance causing the alteration is called the agent drug or the precipitant. The net effects of these interactions are mostly undesirable, leading to decreased effectiveness or increased adverse effects. In rare cases, interactions can be beneficial, such as the enhanced...
329
Therapeutic Drug Monitoring: Affecting Factors
183
Therapeutic Drug Monitoring (TDM) is the clinical practice of measuring specific drug levels in a patient's blood or body tissues to manage and optimize therapy. TDM is crucial for drugs with narrow therapeutic windows, like warfarin and phenytoin, where incorrect doses can lead to treatment failure or severe side effects. This monitoring ensures the dosage administered is within a safe and effective range. The factors affecting therapeutic drug monitoring include:Patient-Specific Factors:a.
183
Combined Effects of Drugs: Antagonism
11.5K
The combined effects of drugs can result in various interactions, of which an important type is antagonism. Antagonism is a mechanism where one drug inhibits or counteracts the effects of another drug. Antagonism can occur through various means, including receptor binding, allosteric modulation, functional interaction, chemical reactions, and pharmacokinetic processes.
The most common type is receptor antagonism, where one drug acts as an antagonist to block the effects of another drug by...
The most common type is receptor antagonism, where one drug acts as an antagonist to block the effects of another drug by...
11.5K
Chemotherapy-Induced Nausea and Vomiting: 5-HT3 Receptor Antagonists
578
5-HT3 receptor antagonists, such as dolasetron, granisetron (Kytril), ondansetron (Zofran), and palonosetron (Axoli), are crucial in managing chemotherapy-induced nausea and vomiting (CINV) and postoperative nausea. These drugs selectively block 5-HT3 receptors in the visceral vagal and spinal afferent nerves, chemoreceptor trigger zone, and the vomiting center. They have a rapid onset of action and can be given as a single dose before chemotherapy. Ondansetron and granisetron, in particular,...
578
Chemotherapy-Induced Nausea and Vomiting: Neurokinin-1 Receptor Antagonists
527
Neurokinin 1 (NK1) receptors are distributed across the GI tract, vagal afferents, and key CNS regions including the central vomiting center and chemoreceptor trigger zone (CTZ) Chemotherapy agents stimulate enterochromaffin cells in the gastrointestinal (GI) tract to release large amounts of substance P (SP). SP is a neuropeptide released by specific sensory nerves in response to many different stressors, including those in the GI mucosa affected by chemotherapy. SP binds and activates...
527


